Nexus Investment Management ULC Acquires Shares of 60,027 Thermo Fisher Scientific Inc. $TMO

Key Points

• Nexus Investment Management ULC has acquired 60,027 shares of Thermo Fisher Scientific Inc., bringing its total investment in the company to approximately $24.3 million.
• Insider trading reports indicate that CEO Marc N. Casper sold 400 shares for around $200,200, reducing his ownership by 0.35%.
• Current stock performance shows TMO trading at around $525.08, with analysts targeting a price range of $460.00 to $589.10 based on recent reports.

Nexus Investment Management ULC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 60,027 shares of the medical research company's stock, valued at approximately $24,339,000. Thermo Fisher Scientific comprises approximately 3.6% of Nexus Investment Management ULC's portfolio, making the stock its 13th biggest position.

Several other hedge funds have also added to or reduced their stakes in TMO. Dash Acquisitions Inc. increased its position in Thermo Fisher Scientific by 5.8% in the second quarter. Dash Acquisitions Inc. now owns 33,796 shares of the medical research company's stock worth $13,703,000 after purchasing an additional 1,844 shares during the period. Smart Portfolios LLC boosted its stake in shares of Thermo Fisher Scientific by 7.1% in the 2nd quarter. Smart Portfolios LLC now owns 780 shares of the medical research company's stock valued at $316,000 after purchasing an additional 52 shares during the last quarter. Rosenberg Matthew Hamilton grew its position in shares of Thermo Fisher Scientific by 24.4% during the 2nd quarter. Rosenberg Matthew Hamilton now owns 1,166 shares of the medical research company's stock worth $473,000 after buying an additional 229 shares during the period. Mutual Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 35.4% during the second quarter. Mutual Advisors LLC now owns 3,266 shares of the medical research company's stock worth $1,324,000 after buying an additional 853 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. boosted its stake in Thermo Fisher Scientific by 7.8% in the second quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 1,799 shares of the medical research company's stock valued at $729,000 after acquiring an additional 130 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last three months. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $525.08 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company's 50 day moving average price is $491.00 and its two-hundred day moving average price is $448.20. The company has a market capitalization of $198.28 billion, a P/E ratio of 30.37, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Robert W. Baird boosted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Finally, William Blair began coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.